Abbvie Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ABBVIE INC, and when can generic versions of ABBVIE INC drugs launch?
ABBVIE INC has fourteen approved drugs.
There are sixty-seven US patents protecting ABBVIE INC drugs.
There are one thousand two hundred and thirty-seven patent family members on ABBVIE INC drugs in fifty-seven countries and one hundred and nineteen supplementary protection certificates in nineteen countries.
Summary for Abbvie Inc
| International Patents: | 1237 |
| US Patents: | 67 |
| Tradenames: | 13 |
| Ingredients: | 13 |
| NDAs: | 14 |
| Drug Master File Entries: | 15 |
| Patent Litigation for Abbvie Inc: | See patent lawsuits for Abbvie Inc |
Drugs and US Patents for Abbvie Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie Inc | MAVYRET | glecaprevir; pibrentasvir | PELLETS;ORAL | 215110-001 | Jun 10, 2021 | RX | Yes | Yes | RE48923*PED | See Plans and Pricing | Y | See Plans and Pricing | |||
| Abbvie Inc | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium; ombitasvir, paritaprevir, ritonavir | TABLET;ORAL | 206619-001 | Dec 19, 2014 | DISCN | Yes | No | 8,642,538 | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| Abbvie Inc | RINVOQ | upadacitinib | TABLET, EXTENDED RELEASE;ORAL | 211675-001 | Aug 16, 2019 | RX | Yes | No | 9,963,459 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Abbvie Inc | ORILISSA | elagolix sodium | TABLET;ORAL | 210450-002 | Jul 23, 2018 | RX | Yes | Yes | 7,056,927 | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| Abbvie Inc | RINVOQ | upadacitinib | TABLET, EXTENDED RELEASE;ORAL | 211675-002 | Jan 14, 2022 | RX | Yes | Yes | RE47221 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Abbvie Inc | RINVOQ | upadacitinib | TABLET, EXTENDED RELEASE;ORAL | 211675-001 | Aug 16, 2019 | RX | Yes | No | 11,186,584 | See Plans and Pricing | Y | See Plans and Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Abbvie Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie Inc | ORILISSA | elagolix sodium | TABLET;ORAL | 210450-001 | Jul 23, 2018 | 7,462,625 | See Plans and Pricing |
| Abbvie Inc | ORILISSA | elagolix sodium | TABLET;ORAL | 210450-002 | Jul 23, 2018 | 6,872,728 | See Plans and Pricing |
| Abbvie Inc | ORILISSA | elagolix sodium | TABLET;ORAL | 210450-002 | Jul 23, 2018 | 7,179,815 | See Plans and Pricing |
| Abbvie Inc | TRICOR | fenofibrate | TABLET;ORAL | 021203-003 | Sep 4, 2001 | 7,037,529 | See Plans and Pricing |
| Abbvie Inc | VIEKIRA XR | dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | TABLET, EXTENDED RELEASE;ORAL | 208624-001 | Jul 22, 2016 | 7,148,359 | See Plans and Pricing |
| Abbvie Inc | ORILISSA | elagolix sodium | TABLET;ORAL | 210450-001 | Jul 23, 2018 | 7,179,815 | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ABBVIE INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 100 mg | ➤ Subscribe | 2010-12-21 |
| ➤ Subscribe | Tablets | 48 mg | ➤ Subscribe | 2008-07-01 |
| ➤ Subscribe | Capsules | 100 mg | ➤ Subscribe | 2012-10-31 |
| ➤ Subscribe | Tablets | 145 mg | ➤ Subscribe | 2007-10-19 |
International Patents for Abbvie Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Poland | 2968301 | See Plans and Pricing |
| Argentina | 109974 | See Plans and Pricing |
| Peru | 20140240 | See Plans and Pricing |
| Australia | 2016204491 | See Plans and Pricing |
| Costa Rica | 20110632 | See Plans and Pricing |
| South Korea | 101920202 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Abbvie Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2203431 | C20150015 00143 | Estonia | See Plans and Pricing | PRODUCT NAME: DASABUVIIR;REG NO/DATE: EU/1/14/983 19.01.2015 |
| 2203431 | PA2015013,C2203431 | Lithuania | See Plans and Pricing | PRODUCT NAME: DASABUVIRAS; REGISTRATION NO/DATE: EU/1/14/983 20150115 |
| 2506716 | 2090010-6 | Sweden | See Plans and Pricing | PRODUCT NAME: UPADACITINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/19/1404 20191218 |
| 2435432 | 300873 | Netherlands | See Plans and Pricing | PRODUCT NAME: VENETOCLAX; REGISTRATION NO/DATE: EU/1/16/1138 20161207 |
| 2368890 | 2015/010 | Ireland | See Plans and Pricing | PRODUCT NAME: OMBITASVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/14/982 20150115 |
| 2435432 | C201730016 | Spain | See Plans and Pricing | PRODUCT NAME: VENETOCLAX; NATIONAL AUTHORISATION NUMBER: EU/1/16/1138; DATE OF AUTHORISATION: 20161205; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/16/1138; DATE OF FIRST AUTHORISATION IN EEA: 20161205 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
